Inpatient COVID-19 Lollipop Study: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Inpatient COVID-19 Lollipop Study (NCT05801341), a na na study. The primary outcome is Tabulated Results From Nasopharyngeal (NP) vs Lollipop Swab-based PCR Covid-19 Tests.

2. Clinical Question

3. Trial Design

The Inpatient COVID-19 Lollipop Study is a diagnostic-test study registered as NCT05801341. The registry lists its phase as NA, allocation as NA, masking as none, and model as single-group. It lists the lollipop as the intervention and describes the participants as COVID-19 positive, determined by NP PCR. These features distinguish the study from a randomized trial assigning participants to separate treatment arms. The registry itself cautions that this is not a randomized comparison and that its arms are not a like-for-like control comparison.

The study description proposed enrolling 225 COVID-positive participants aged 4 years and above, admitted to a hospital in the Madison, Wisconsin metropolitan area, over a 6 month period. The registry reports enrollment of 17 and status as terminated. The start date is 2023-04-20, and the primary completion date is 2023-05-24. The reason for termination and whether the planned recruitment period was completed are not reported in the registry record. The planned enrollment should not be mistaken for the number enrolled.

The primary outcome is titled as tabulated results from NP versus lollipop swab-based PCR tests and is defined as the count of tests that detected COVID-19. Its timeframe is 1 study visit, with data collected in 20 seconds. The registry also lists outcomes concerning discordant test results and clinical characteristics. It does not provide the results for these measures or describe the analysis population. Whether the same participants contributed results for both collection methods, and how missing or indeterminate test results were handled, are not reported in the registry record.

Because the record presents a diagnostic comparison within a single-group study, the design and its reporting should be read as a test-evaluation question, not as evidence from a randomized intervention comparison. The registry does not report a masking procedure, a control group, or an analysis plan that would support further claims about allocation or adjustment.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Tabulated Results From Nasopharyngeal (NP) vs Lollipop Swab-based PCR Covid-19 Tests, measured over 1 study visit (data collected in 20 seconds).

The primary endpoint is the count of tests that detected COVID-19, comparing NP and lollipop swab-based PCR tests. It is a count outcome: it records detections rather than a continuous measurement such as a laboratory concentration. The registry identifies the measurement unit as COVID-19 tests and places collection at 1 study visit, with data collected in 20 seconds.

Counts can describe how many tests yielded a positive detection, but the count alone does not establish the proportion of tests that were positive, the accuracy of either test, or the degree of agreement between methods. Interpreting a count generally requires knowing which tests were included, the number of opportunities to test, and how discordant, missing, or inconclusive results were handled. Those details and the primary outcome values are not reported in the registry record.

The endpoint is relevant to the stated diagnostic question because the study set out to compare COVID-19 detection using lollipop-collected oral samples with detection using NP samples. A count of detections may contribute to that comparison, while the separately listed discordant-results outcome could describe instances in which results differed. The registry does not report results for either measure, so no estimate of relative detection or agreement can be drawn from the record.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry describes the primary measure as a count of tests that detected COVID-19. A count is a discrete outcome: it records events in whole units rather than measurements on a continuous scale. Describing a count can be useful when the question concerns how many test results detected the condition. A count by itself, however, is not a rate or a proportion. To interpret it as a fraction of tested samples, the relevant denominator and the rules defining an evaluable test result must also be known. The registry does not report the primary count values or the denominators used.

What does a count comparison tell a reader?

In general, counts can be compared descriptively across testing methods, but interpretation depends on how the data were collected. If methods are applied to the same participants, the relationship between each participant’s results may matter. If different participants contribute to each method, the comparison has a different structure. The registry identifies a single-group model and an NP-versus-lollipop testing question, but the detailed pairing and analysis structure are not reported in the registry record. It is therefore not possible to infer a specific statistical test or to reconstruct an analysis.

Discordance is a separate concept from the total number of positive detections. It refers generally to cases in which two methods give different results for the same evaluation. A discordant-results count can help describe agreement, but the count requires context: the full pattern of positive and negative results, the number of paired evaluations, and any handling of inconclusive or missing results. The registry lists discordant test results as a secondary outcome but does not report its value or the underlying result pattern.

Why does design matter?

A randomized comparison uses a specified allocation process to create comparison groups. This record lists allocation as NA and describes a single-group study, and its own note warns that the arms are not a like-for-like control comparison. General statistical interpretation must respect that design information. A result from a nonrandomized diagnostic comparison would not automatically have the same interpretation as a randomized treatment effect. Moreover, this record does not report enough detail to determine the precise structure of the test comparison.

Masking is listed as none. In general, masking can reduce the influence of knowledge about a prior result or participant status on later assessment, but its relevance depends on the procedures and the outcome. The registry does not describe further masking or laboratory procedures. No inference should be made about whether result interpretation was independent of other test results.

What can uncertainty estimates add?

In general, a confidence interval describes a range of values compatible with an estimate under the assumptions of a statistical model. It conveys precision as well as the estimate’s direction and magnitude. A count without an estimate of uncertainty is less informative about how stable the observed pattern may be beyond the recorded data. The registry does not report outcome estimates or confidence intervals, so precision cannot be evaluated.

Some count outcomes can show over-dispersion, meaning that observed variability is greater than a simple model assumes. In general, this can make standard errors too small if the model does not allow for the extra variability. Whether over-dispersion is relevant depends on the data structure and model. The registry lists no analyses and does not report a model, dispersion estimate, or statistical plan, so no specific modeling choice can be attributed to this study.

How should planning illustrations be read?

Any sample-size illustration based on an observed effect is a planning exercise, not an observed measure of power. The registry record states assumptions of a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation; it also says the effect to detect is a stated fraction of the observed effect. For non-time-to-event outcomes, such illustrations are expressed as participants per arm for 80% or 90% power; time-to-event illustrations use total events. These assumptions do not describe the study’s allocation, because the registry lists allocation as NA and a single-group model. The observed effect needed for such an illustration is not reported in the registry record, and the illustrations cannot be treated as the study’s original design or as observed power.

The registry lists 0 analyses. This means the record does not provide a statistical analysis entry to clarify hypotheses, methods, adjustment, or uncertainty reporting. The method actually used to evaluate the primary endpoint is not reported in the registry record. General explanations of counts, discordance, confidence intervals, or over-dispersion describe statistical concepts; they are not evidence that a particular method was used in this study.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists 5 outcome measures: the primary count of tests detecting COVID-19 and secondary outcomes concerning discordant test results and clinical characteristics. Considering multiple outcomes can raise a general multiplicity issue: when several hypotheses are tested, the chance of at least one apparently notable result may increase if no adjustment or prespecified hierarchy is used. The registry does not report a multiplicity strategy, a hierarchy among secondary outcomes, or a statistical analysis plan. Because no analyses or outcome values are listed, it is not possible to determine whether any adjustment was used or how it would affect interpretation.

Missing-data handling is also not described. The registry does not report whether any tests were missing, inconclusive, invalid, or excluded, or how any such results were handled. It does not state whether the analysis included all enrolled participants or only participants with results available for both collection methods. The analysis population is not reported in the registry record.

These omissions matter in diagnostic comparisons because the set of evaluable tests affects counts and any comparison derived from them. A reader cannot assume that every enrolled participant contributed a complete result for each method. The enrollment figure alone does not establish the number of paired or evaluable tests. The registry record does not report participant-level flow, exclusions, or missing-result counts, so the potential effect of missing data cannot be assessed.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

The registry’s adverse-event figures list 17 participants at risk for serious adverse events and 0 with a serious adverse event; deaths are reported as 0. For other adverse events, the record also lists 17 at risk and 0 affected. These are registry counts, not estimates of risk for a broader population, and the figures do not establish that every participant experienced the same follow-up or had complete safety reporting.

The study is a diagnostic collection-method study, and the listed intervention is the lollipop device. The record does not provide details about the adverse-event collection period, event definitions, ascertainment procedures, or whether events were considered related to the device or procedure. It also lists no top serious-event terms. The absence of reported serious events in these figures should not be interpreted as proof that the collection method is free of risk. The registry’s status is terminated, but the reason for termination is not reported, and no explanation of its relationship, if any, to safety is given.

12. What the Result Does, and Does Not, Mean

The record describes a study intended to examine whether oral samples collected using a lollipop could detect COVID-19 by PCR in comparison with NP samples. It reports an enrollment of 17, a single-group model, no masking, and terminated status. It also specifies a primary outcome based on the count of tests detecting COVID-19 and lists discordant results among the secondary outcomes.

Those design and registration details do not provide the study’s findings. The primary count, the discordant-result count, clinical-characteristic summaries, and statistical estimates are not reported in the registry record. Thus, the posted information does not show whether one method detected more cases, whether results agreed, or how precise any comparison would be. It cannot establish diagnostic sensitivity, specificity, equivalence, or noninferiority.

The planned enrollment of 225 is distinct from the registry-reported enrollment of 17. The record does not explain the difference or the termination. These registry entries may be important context for assessing the completeness of the evidence, but they do not reveal the reason for stopping or the unreported test outcomes.

In general, diagnostic evidence depends on the test-result patterns, an appropriate reference method, and a transparent account of missing and inconclusive results. A count of detections alone would not necessarily answer every question about test performance. The registry record does not report enough data to assess those features. The appropriate conclusion is limited: the registry documents the study’s question and design, while the posted results do not provide the outcome data needed to judge the comparison.

13. Why This Trial Matters Statistically

This study raises a useful statistical question about diagnostic tests: how should evidence be described when the aim is to compare two ways of collecting a sample, but the registry identifies a single-group design rather than a randomized comparison? The distinction matters because statistical conclusions depend on how participants and tests are organized, not just on the names of the methods being compared. Here, the record explicitly cautions that the arms are not a like-for-like control comparison.

The registry also illustrates the difference between an intended enrollment and reported enrollment. The description planned 225 participants, while the record reports enrollment of 17 and terminated status. That context affects how much information readers might expect, but it does not substitute for outcome reporting. A clear account of the observed test results, denominators, discordance, exclusions, and analysis methods would be needed to evaluate the diagnostic question.

Counts are easy to state, but their meaning depends on the underlying data structure. In diagnostic work, readers generally need to know whether methods were assessed on the same participants and how missing or indeterminate results were handled. Those details support appropriate estimates of agreement or performance and help readers understand uncertainty. They are not reported in the registry record.

The statistical importance of this record is therefore partly about limits of interpretation. It documents a focused diagnostic question, but lists 0 analyses and does not report the primary or secondary outcome values. Recognizing the boundary between a registered question and an interpretable result is essential: study intent, enrollment, and safety counts cannot replace the test-result data needed to assess diagnostic performance.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The registry record has important limitations for interpreting this study. The primary outcome is defined, but its value is not reported. The secondary outcome values are also not reported, including discordant test results and clinical-characteristic summaries. No estimates of effect, uncertainty intervals, or analysis results are listed, and the record lists 0 analyses.

The study description planned enrollment of 225, whereas the registry reports enrollment of 17 and status as terminated. The reason for termination, recruitment progress, and relationship between the planned and actual enrollment are not reported in the registry record. The participant characteristics and age distribution are also not reported. The record therefore does not establish how representative the enrolled participants were of the intended population.

Although NP and lollipop swab-based PCR testing are named, the detailed comparison structure is unclear. The record does not state whether every participant had both tests, how results were paired, or how missing, invalid, or inconclusive results were handled. It gives no analysis population or statistical plan. These gaps prevent assessment of agreement, diagnostic performance, precision, or potential bias.

The registry notes that the study was not randomized and that arms are not a like-for-like control comparison. This is a further reason not to interpret it as a randomized comparison. The status of masking is listed as none, but procedures for test processing and result interpretation are not described. Finally, the safety counts lack details about ascertainment and follow-up. The record supports a description of the registered design and reported counts, but not a conclusion about test performance or comprehensive safety.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Inpatient COVID-19 Lollipop Study — NCT05801341.
• Registry record last updated 2024-06-07; status last verified 2024-06.
• Results first posted 2024-05-23.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

NCT05801341, the Inpatient COVID-19 Lollipop Study, was registered to assess lollipop oral-swab collection for COVID-19 PCR testing in an inpatient setting, with NP swab-based PCR as the comparison. The registry lists the model as single-group, allocation as NA, masking as none, and status as terminated. Enrollment is reported as 17. The study description planned 225 COVID-positive participants aged 4 years and above over a 6 month period.

The primary outcome was the count of tests detecting COVID-19 at 1 study visit, with data collected in 20 seconds. The record lists 5 outcome measures and 0 analyses, but does not report primary or secondary outcome values or explain the termination. Safety figures list 0 serious adverse events and 0 deaths. The posted record describes the study question and selected design details, but does not contain the test-result data needed to evaluate the diagnostic comparison.